Experts tout amylin as promising, potentially gentler obesity target as new combo therapies near FDA review

While GLP-1 medicines dominate the weight‑loss market, some observers argue that amylin would have been the logical primary target for obesity treatment a decade ago.

Novo Nordisk’s amylin/GLP‑1 combination, CagriSema, is reported to be nearing possible FDA approval, and late‑stage data are emerging from amylin‑focused programs at Eli Lilly and Zealand Pharma.

Hyung Heon Kim, CEO of MetaVia, and BMO Capital Markets analyst Evan Seigerman both highlighted amylin’s potential for better tolerability and called it the next hot target in the obesity space.

The discussion signals growing industry interest in exploring gentler mechanisms for weight management as an alternative to the widely used GLP‑1 drugs.